Irbesartan Tablet
NDC 62135-976
Product Information
Irbesartan is a ANDA-approved product labeled by Chartwell Rx, Llc. Irbesartan is used to treat high blood pressure (hypertension) and to help protect the kidneys from damage due to diabetes. It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 62135-976 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
CE;283
Code Structure Chart
Product Details
What is NDC 62135-976?
What are the uses of this product?
What are Active Ingredients of this product?
- IRBESARTAN 75 mg/1 - A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- IRBESARTAN (UNII: J0E2756Z7N)
- IRBESARTAN (UNII: J0E2756Z7N) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CARBOXYMETHYLCELLULOSE CALCIUM (UNII: UTY7PDF93L)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
- POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 200094 - irbesartan 75 MG Oral Tablet
- RxCUI: 200095 - irbesartan 150 MG Oral Tablet
- RxCUI: 200096 - irbesartan 300 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.